Efficacy and safety of endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors (TKI) after programmed cell death 1 (PD-1) inhibitor treatment in patients with metastatic clear cell renal cell carcinoma (mccRCC).

被引：62

作者：

Nadal, Rosa

Amin, Asim

Geynisman, Daniel M.

Voss, Martin Henner

Weinstock, Matthew

Doyle, Jaime

Zhang, Zhe

Viudez, Antonio

Plimack, Elizabeth R.

McDermott, David F.

Motzer, Robert

Rini, Brian I.

Hammers, Hans J.

机构：

[1] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[2] Levine Canc Inst, Charlotte, NC USA

[3] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA

[4] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[5] BIDMC, Cambridge, MA USA

[6] Temple Univ Hlth Syst, Fox Chase Canc Ctr, Philadelphia, PA USA

[7] Johns Hopkins Kimmel Canc Ctr, Baltimore, MD USA

[8] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA

[9] Taussig Canc Inst, Cleveland, OH USA

来源：

关键词：

D O I：

10.1200/jco.2015.33.15_suppl.4566

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4566

引用

页数：1